Effect of 50% human serum on the killing activity of micafungin against eight Candida species using time-kill methodology

Diagnostic Microbiology and Infectious Disease

Volumn 73, Issue 4, 2012, Pages 338-342

  Földi, Richárd ^a   Szilágyi, Judit ^a   Kardos, Gábor ^a   Berényi, Réka ^a   Kovács, Renátó ^a   Majoros, László ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Antifungal susceptibility; Echinocandins; Impaired killing; Serum based susceptibility testing

Indexed keywords

ECHINOCANDIN; MICAFUNGIN;

ARTICLE; CANDIDA; CANDIDA ALBICANS; CANDIDA INCONSPICUA; CANDIDA KRUSEI; CANDIDA METAPSILOSIS; CANDIDA ORTHOPSILOSIS; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; COLONY FORMING UNIT; CONCENTRATION RESPONSE; CONTROLLED STUDY; FUNGAL STRAIN; FUNGICIDAL ACTIVITY; FUNGUS GROWTH; FUNGUS ISOLATION; HUMAN; HUMAN CELL; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

ANTIFUNGAL AGENTS; CANDIDA; CULTURE MEDIA; ECHINOCANDINS; HUMANS; LIPOPEPTIDES; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; SERUM; TIME FACTORS;

EID: 84863783265     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2012.05.011     Document Type: Article

References (25)

1. Arendrup M.C., Rodriguez-Tudela J.L., Park S., Garcia-Effron G., Delmas G., Cuenca-Estrella M., et al. Echinocandin susceptibility testing of Candida spp. Using EUCAST EDef 7.1 and CLSI M27-A3 standard procedures: analysis of the influence of bovine serum albumin supplementation, storage time, and drug lots. Antimicrob Agents Chemother 2011, 55:1580-1587.
2. Baltch A.L., Ritz W., Bopp L.H., Michelsen P.B., Smith R.P. Time-kill studies with micafungin and voriconazole against Candida glabrata intracellularly in human monocyte-derived macrophages and extracellularly in broth. Diagn Microbiol Infect Dis 2011, 70:468-474.
3. Betts R.F., Nucci M., Talwar D., Gareca M., Queiroz-Telles F., Bedimo R.J., et al. A multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis. Clin Infect Dis 2009, 48:1676-1684.
4. Chen S.C., Slavin M.A., Sorrell T.C. Echinocandin antifungal drugs in fungal infections: a comparison. Drugs 2011, 71:11-41.
5. Clinical and Laboratory Standards Institute (CLSI) Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard, third edition, M27-A3 2008, CLSI, Wayne, PA.
6. Ernst E.J., Roling E.E., Petzold C.R., Keele D.J., Klepser M.E. In vitro activity of micafungin (FK-463) against Candida spp.: microdilution, time-kill, and postantifungal-effect studies. Antimicrob Agents Chemother 2002, 46:3846-3853.
7. Garcia-Effron G., Katiyar S.K., Park S., Edlind T.D., Perlin D.S. A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis and Candida metapsilosis accounts for reduced echinocandin susceptibility. Antimicrob Agents Chemother 2008, 52:2305-2312.
8. Garcia-Effron G.S., Park S., Perlin D.S. Improved detection of Candida sp. fks hot spot mutants by using the method of the CLSI M27-A3 Document with the addition of bovine serum albumin. Antimicrob Agents Chemother 2011, 55:2245-2255.
9. Goto N., Hara T., Tsurumi H., Ogawa K., Kitagawa J., Kanemura N., et al. Efficacy and safety of micafungin for treating febrile neutropenia in hematological malignancies. Am J Hematol 2010, 85:872-876.
10. Hiemenz J., Cagnoni P., Simpson D., Devine S., Chao N., Keirns J., et al. Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant. Antimicrob Agents Chemother 2005, 49:1331-1336.
11. Howard S.J., Livermore J., Sharp A., Goodwin J., Gregson L., Alastruey-Izquierdo A., et al. Pharmacodynamics of echinocandins against Candida glabrata: requirement for dosage escalation to achieve maximal antifungal activity in neutropenic hosts. Antimicrob Agents Chemother 2011, 55:4880-4887.
12. Ishikawa J., Maeda T., Matsumura I., Yasumi M., Ujiie H., Masaie H., et al. Antifungal activity of micafungin in serum. Antimicrob Agents Chemother 2009, 53:4559-4562.
13. Kabbara N., Lacroix C., Peffault de Latour R., Socie G., Ghannoum M., Ribaud P. Breakthrough C. parapsilosis and C. guilliermondii blood stream infections in allogeneic hematopoietic stem cell transplant recipients receiving long-term caspofungin therapy. Haematologica 2008, 93:639-640.
14. Majoros L., Kardos G., Belák Á., Maráz A., Asztalos L., Csánky E., et al. Restriction enzyme analysis of ribosomal DNA shows that Candida inconspicua clinical isolates can be misidentified as Candida norvegensis with traditional diagnostic procedures. J Clin Microbiol 2003, 41:5250-5253.
15. Odabasi Z., Paetznick V., Rex J.H., Ostrosky-Zeichner L. Effects of serum on in vitro susceptibility testing of echinocandins. Antimicrob Agents Chemother 2007, 51:4214-4216.
16. Paderu P., Garcia-Effron G., Balashov S., Delmas G., Park S., Perlin D.S. Serum differentially alters the antifungal properties of echinocandin drugs. Antimicrob Agents Chemother 2007, 51:2253-2256.
17. Pappas P.G., Rotstein C.M.F., Betts R.F., Nucci M., Talwar D., De Waele J.J., et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007, 45:883-893.
18. Pappas P.G., Kauffman C.A., Andes D., Benjamin D.K., Calandra T.F., Edwards J.E., et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009, 48:503-535.
19. Pfaller M.A., Diekema D.J., Andes D., Arendrup M.C., Brown S.D., Lockhart S.R., et al. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist Updat 2011, 14:164-176.
20. Pfeiffer C.D., Garcia-Effron G., Zaas A.K., Perfect J.R., Perlin D.S., Alexander B.D. Breakthrough invasive candidiasis on micafungin. J Clin Microbiol 2010, 48:2373-2380.
21. Sirohi B., Powles R.L., Chopra R., Russell N., Byrne J.L., Prentice H.G., et al. A study to determine the safety profile and maximum tolerated dose of micafungin (FK463) in patients undergoing haematopoietic stem cell transplantation. Bone Marrow Transplant 2006, 38:47-51.
22. Stein G.E., El-Mortada M., Smith C., Dybas L., Prince R., Havlichek D. Fungicidal activity of anidulafungin in serum from patients does not correlate to its susceptible breakpoint against Candida spp. J Antimicrob Chemother 2010, 65:374-376.
23. Tavanti A., Davidson A.D., Gow N.A., Maiden M.C., Odds F.C. Candida orthopsilosis and Candida metapsilosis spp. nov. to replace Candida parapsilosis groups II and III. J Clin Microbiol 2005, 43:284-292.
24. Undre N., Stevenson P., Baraldi E. Pharmacokinetics of micafungin in HIV positive patients with confirmed esophageal candidiasis. Eur J Drug Metab Pharmacokinet 2012, 37:31-38.
25. Yamada N., Kumada K., Kishino S., Mochizuki N., Ohno K., Ogura S. Distribution of micafungin in the tissue fluids of patients with invasive fungal infections. J Infect Chemother 2011, 17:731-734.